ACLA Has its Say Regarding Molecular Dx Proposals

CEO SUMMARY: It is not known how many public comments have been submitted to Palmetto GBA, the big Medicare carrier, in response to its published proposals to change how code stacked claims for genetic and molecular tests will be handled, effective February 27, 2012, for labs in Medicare region J1. After filing its comments, the …

ACLA Has its Say Regarding Molecular Dx Proposals Read More »

To access this post, you must purchase The Dark Report.

ACLA Has its Say Regarding Molecular Dx Proposals

In a 23-page public comment letter, lab group takes issue with Palmetto GBA’s draft proposals

Comments

TABLE OF CONTENTS

Need A Group Membership? Company Discounts are Available!

You are reading premium content from The Dark Report, your primary resource for running an efficient and profitable laboratory.

Get Unlimited Access to The Dark Report absolutely FREE!

You have read 0 of 1 of your complimentary articles this month

You have read 0 of 1 of your complimentary articles this month